EUVIMEDEUVIMED entdecken
Crossref

Effects of bevacizumab combined with anti-epidermal growth factor receptor monoclonal antibody-targeted drugs in patients with metastatic colorectal cancer

Zhehui Lin

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-025-04921-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Zhehui Lin. Beteiligte Einrichtung: Department of General Surgery, Fuzhou Taijiang Hospital, Fuzhou, Fujian Province, 350000, China. zhehuilin25@163.com. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Bevacizumab, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is a common malignant tumor of the digestive system. The standard chemotherapy (CT) regimen for metastatic CRC (mCRC) is FOLFIRI, etc., but CT plus bevacizumab anti-epidermal growth factor receptor (EGFR)monoclonal antibody (mAb) (cetuximab) can improve the therapeutic effect. This article compared the effect of FOLFIRI plus bevacizumab on the clinical treatment of mCRC. One hundred eight patients with mCRC were divided into cohort A (CA, bevacizumab FOLFIRI CT, n = 50) and cohort B (CB, cetuximab + FOLFIRI CT, n = 58). All patients received 6 cycles of CT. The levels of tumor markers, angiogenic factors, and T lymphocyte subsets were compared, and the objective response rate (ORR) and disease control rate (DCR) were counted. The overall survival (OS), progression-free survival (PFS), and adverse reactions (AR) were recorded. There was no difference in DCR (82.0% vs 89.7%), serum tumor markers, angiogenic factors, T lymphocyte subsets (CD3 + , CD4 + , and CD8 +), and DFS (16.0% vs 24.1%) in subjects; as against CA, the ORR (62.0% vs 75.9%), CD4 + /CD8 + ratio, and OS (32.0% vs 46.6%) were significantly increased, and the VEGF level was significantly higher in CB (P < 0.05). Compared with bevacizumab plus FOLFIRI, cetuximab plus FOLFIRI has significantly higher ORR and longer OS in the treatment of patients with mCRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsBevacizumabAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedLeucovorinAgedCamptothecinFluorouracilAdultErbB ReceptorsCetuximabProgression-Free SurvivalAntineoplastic Agents, ImmunologicalAged, 80 and over

Stichwörter der Autor:innen

Angiogenic factorsBevacizumabCetuximabMCRCT lymphocyte subsetsTumor markers

Substanzen

BevacizumabLeucovorinCamptothecinFluorouracilErbB ReceptorsCetuximabEGFR protein, humanAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of General Surgery, Fuzhou Taijiang Hospital, Fuzhou, Fujian Province, 350000, China. zhehuilin25@163.com.

Zitieren

APA

Lin, Z. (2026). Effects of bevacizumab combined with anti-epidermal growth factor receptor monoclonal antibody-targeted drugs in patients with metastatic colorectal cancer. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04921-2

Vancouver

Lin Z. Effects of bevacizumab combined with anti-epidermal growth factor receptor monoclonal antibody-targeted drugs in patients with metastatic colorectal cancer. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-025-04921-2

BibTeX
@article{Lin2026,
  author = {Lin, Zhehui},
  title = {Effects of bevacizumab combined with anti-epidermal growth factor receptor monoclonal antibody-targeted drugs in patients with metastatic colorectal cancer},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-025-04921-2}
}
Kostenlos starten →